Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Dosebestemmelsesstudie av ORKA-001 hos pasienter med moderat til alvorlig plakkpsoriasis (EVERLAST-B)

3. november 2026 oppdatert av: Oruka Therapeutics, Inc.

En multicenter, randomisert, dobbeltblindet, placebokontrollert, doseringsfinneundersøkelse av ORKA-001 hos deltakere med moderat til alvorlig plakkpsoriasis

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Detaljert beskrivelse

This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.

The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.

The study will consist of 4 periods:

  • Screening Period of up to 6 weeks
  • Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
  • Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
  • Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.

Studietype

Intervensjonell

Registrering (Antatt)

160

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • British Columbia
      • Surrey, British Columbia, Canada, V3R 6A7
        • Oruka Therapeutics Investigative Site
      • Surrey, British Columbia, Canada, V3V 0C6
        • Oruka Therapeutics Investigative Site
    • New Brunswick
      • Fredericton, New Brunswick, Canada, E3B 1G9
        • Oruka Therapeutics Investigative Site
    • Ontario
      • Ajax, Ontario, Canada, L1S 7K8
        • Oruka Therapeutics Investigative Site
      • Markham, Ontario, Canada, L3P 1X3
        • Oruka Therapeutics Investigative Site
      • Peterborough, Ontario, Canada, K9J 5K2
        • Oruka Therapeutics Investigative Site
    • Quebec
      • Montreal, Quebec, Canada, HZX 2V1
        • Oruka Therapeutics Investigative Site
      • Québec, Quebec, Canada, G1V 4X7
        • Oruka Therapeutics Investigative Site
    • Arizona
      • Phoenix, Arizona, Forente stater, 85032
        • Oruka Therapeutics Investigative Site
    • Arkansas
      • North Little Rock, Arkansas, Forente stater, 72117
        • Oruka Therapeutics Investigative Site
    • California
      • Los Angeles, California, Forente stater, 90045
        • Oruka Therapeutics Investigative Site
      • Los Angeles, California, Forente stater, 90024
        • Oruka Therapeutics Investigative Site
      • San Diego, California, Forente stater, 92123
        • Oruka Therapeutics Investigative Site
    • Florida
      • Miami, Florida, Forente stater, 33126
        • Oruka Therapeutics Investigative Site
    • Illinois
      • Rolling Meadows, Illinois, Forente stater, 60008
        • Oruka Therapeutics Investigative Site
    • Indiana
      • Plainfield, Indiana, Forente stater, 46168
        • Oruka Therapeutics Investigative Site
    • Maryland
      • Rockville, Maryland, Forente stater, 20850
        • Oruka Therapeutics Investigative Site
    • New York
      • Kew Gardens, New York, Forente stater, 11415
        • Oruka Therapeutics Investigative Site
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27516
        • Oruka Therapeutics Investigative Site
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Oruka Therapeutics Investigative Site
      • Mason, Ohio, Forente stater, 45040
        • Oruka Therapeutics Investigative Site
    • Oregon
      • Portland, Oregon, Forente stater, 97201
        • Oruka Therapeutics Investigative Site
      • Portland, Oregon, Forente stater, 97210
        • Oruka Therapeutics Investigative Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Oruka Therapeutics Investigative Site
    • Texas
      • Frisco, Texas, Forente stater, 75033
        • Oruka Therapeutics Investigative Site
      • Houston, Texas, Forente stater, 77004
        • Oruka Therapeutics Investigative Site
      • Webster, Texas, Forente stater, 77598
        • Oruka Therapeutics Investigative Site
    • Virginia
      • Norfolk, Virginia, Forente stater, 23502
        • Oruka Therapeutics Investigative Site
    • Barcelona
      • Badalona, Barcelona, Spania, 08916
        • Oruka Therapeutics Investigative Site
      • Barcelona, Barcelona, Spania, 08041
        • Oruka Therapeutics Investigative Site
    • Madrid
      • Madrid, Madrid, Spania, 28002
        • Oruka Therapeutics Investigative Site
      • Madrid, Madrid, Spania, 28046
        • Oruka Therapeutics Investigative Site
    • Baden-Wuerrtemberg
      • Heidelberg, Baden-Wuerrtemberg, Tyskland, 69120
        • Oruka Therapeutics Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60590
        • Oruka Therapeutics Investigative Site
    • Lower Saxony
      • Bad Bentheim, Lower Saxony, Tyskland, 48455
        • Oruka Therapeutics Investigative Site
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Tyskland, 24105
        • Oruka Therapeutics Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Participants ≥ 18 years of age

  2. Have a diagnosis of plaque psoriasis for > 6 months

  3. Have moderate-to-severe chronic plaque psoriasis defined as:

    1. BSA ≥ 10%, and
    2. PASI ≥ 12, and
    3. IGA score of ≥ 3 on a 5-point scale
  4. Candidate for systemic therapy or phototherapy

  5. Women of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
  2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
  3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
  4. A known hypersensitivity to any components of the ORKA-001 drug product
  5. Women who are breastfeeding or plan to breastfeed during the study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: (Induction Period - Arm 1) ORKA-001

Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentell: (Induction Period - Arm 2) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentell: (Induction Period - Arm 3) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Placebo komparator: (Induction Period - Arm 4) Placebo

Participants will receive Placebo per protocol Induction regimen.

Placebo administered by subcutaneous (SC) injection

Eksperimentell: (Maintenance Period - Arm 1) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentell: (Maintenance Period - Arm 2) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

Placebo komparator: (Maintenance Period - Arm 3) Placebo

Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.

Placebo administered by subcutaneous (SC) injection

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
Tidsramme: Week 16

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
Tidsramme: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
Tidsramme: Week 16

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
Tidsramme: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
Tidsramme: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
Tidsramme: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
Tidsramme: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
Tidsramme: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
Tidsramme: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
Tidsramme: Day 1 through Week 100

Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms

Day 1 through Week 100

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. desember 2025

Primær fullføring (Faktiske)

21. oktober 2026

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

16. desember 2025

Først innsendt som oppfylte QC-kriteriene

16. desember 2025

Først lagt ut (Faktiske)

18. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ORKA-001-114

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere